COVID vaccine maker BioNTech buys Gaithersburg facility

Pfizer COVID-19 vaccine production partner BioNTech is buying a manufacturing facility in Gaithersburg, Maryland, where the German company will advance development of its personalized cell therapies for cancer.

BioNTech is buying the facility from Kite Pharma, a subsidiary of Gilead Sciences. It is also acquiring Kite’s platform for developing T-cell receptor immunotherapies. It will retain Kite’s current lab employees in Gaithersburg, and said it will hire more people. Kite has a separate, new facility in Frederick, Maryland, which is not part of its deal with BioNTech.

“The acquisition of the Kite facility and its individualized TCR platform allows us to accelerate the clinical development of our cell therapies in the U.S. and advance at the forefront of individualized cell therapies,” said BioNTech CEO Ugur Sahin.

Montgomery County is home to the Food and Drug Administration, National Institutes of Health and the National Cancer Institute.

BioNTech joins many other biotech and life sciences companies with operations in Montgomery County, which the Montgomery County Economic Development Corporation refers to as the Immunology Capital.

Jeff Clabaugh

Jeff Clabaugh has spent 20 years covering the Washington region's economy and financial markets for WTOP as part of a partnership with the Washington Business Journal, and officially joined the WTOP newsroom staff in January 2016.

Like WTOP on Facebook and follow @WTOP on Twitter to engage in conversation about this article and others.

Get breaking news and daily headlines delivered to your email inbox by signing up here.

© 2021 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

More from WTOP

Log in to your WTOP account for notifications and alerts customized for you.

Sign up